Boehringer Ingelheim to Pay $95 Million to Resolve False Claims Act Allegations
October 26, 2012 | Posted By: Hoyer Law Group, PLLC
Government Alleges Company Improperly Marketed Three Drugs Connecticut-based Boehringer Ingelheim Pharmaceuticals Inc. has agreed to pay $95 million to resolve allegations relating to the improper promotion of the stroke-prevention drug Aggrenox, the chronic obstructive pulmonary disease (COPD) drugs Atrovent and Combivent, and the hypertension drug Micardis, the Justice Department announced today. The Food and Drug […]
Learn More